Nvidia Rides Pharma AI Factory and KeyBanc Upgrade to Counter Semiconductor Bear Market

Nvidia ekes out gains despite Philadelphia Semiconductor Index entering bear territory, boosted by KeyBanc's $330 target and Bristol Myers Squibb's AI factory deal using Vera-Rubin systems.

The Philadelphia Semiconductor Index has tumbled into bear-market territory, shedding roughly ten percent in a single week, yet Nvidia shares eked out a 1.44% gain in Frankfurt on Monday to 180.02 euros. The chipmaker remains 11.10% below its 52-week high of 202.50 euros from May, but a flurry of company-specific bullish signals — a key analyst upgrade, a high-profile pharmaceutical AI factory deal, and fresh software ecosystem moves — are providing a counterweight to the broader sector’s nervousness.

KeyBanc analyst John Vinh raised his price target on Nvidia from $310 to $330, reaffirming an Overweight rating after conducting proprietary supply-chain checks in Asia. Vinh’s optimism is anchored on expected deliveries of 5.5 million to 6 million Blackwell GPUs and 1.7 million to 1.8 million Rubin GPUs in 2026, alongside 70,000 to 80,000 rack orders. He acknowledged a minor delay in the thermal design and HBM4 qualification for the Rubin architecture but deemed the risk low.

The analyst upgrade lands amid sharply divided views on Nvidia’s near-term trajectory. Morgan Stanley’s Joseph Moore calls Nvidia alongside Broadcom the best chip stock after the sell-off, while Mizuho’s Vijay Rakesh argues the sector still has “plenty of gas in the tank” thanks to ongoing AI investment. JPMorgan expects supply-demand dynamics in semiconductors to remain broadly unchanged through at least 2028, suggesting bargains will soon attract buyers. On the bearish side, investor David Desjardins placed a “Strong Sell” rating on Nvidia, citing physical constraints in power grids and supply chains that could slow hyperscaler spending. Meanwhile, Goldman Sachs reported that hedge funds trimmed US tech exposure by roughly ten percent over two months — the fastest pace in over a decade — with net sales in six of the past eight weeks. Still, the Wall Street consensus remains heavily bullish, with 36 buy ratings against one hold and an average price target around $310.

Concrete demand from outside the pure-play tech world arrived in the form of a major expansion of Nvidia’s partnership with Bristol Myers Squibb. The pharmaceutical giant is building one of the life-sciences industry’s most powerful AI factories, leveraging Nvidia’s new DGX Vera-Rubin-NVL72 systems. The Vera-Rubin architecture promises up to ten times more performance per megawatt than its Blackwell predecessors. BMS plans to apply that computing muscle to accelerate oncology, cardiovascular, and immunology research; its “Predict First” approach now guides nearly all small-molecule drug programs, with AI agents identifying and validating targets before lab work begins. The deal came on the same day that Elon Musk dismissed as “fake news” a report that SpaceX had placed a $52 billion order for roughly one million GB300 chips via Foxconn — a rumor that, had it been true, would have underscored the scale of demand for Nvidia’s next-generation silicon. Separately, cloud provider QumulusAI confirmed the purchase of 1,632 Blackwell B300 chips to meet rising customer demand.

Nvidia also used the SIGGRAPH conference in Los Angeles to expand its software arsenal, unveiling the Cosmos 3 Edge physical AI model and integrating Omniverse libraries into its Agent Toolkit. Partners such as SideFX and PTC are already embedding the libraries to streamline CAD workflows and product-data management. The software push dovetails with Nvidia’s hardware ambitions, equipping autonomous systems to train and test in simulated 3D environments. Beyond the SIGGRAPH announcements, Nvidia deepened its strategic ties with Palantir to help government agencies build sovereign AI systems and disclosed in a Schedule 13G filing a 9.3% stake in cloud provider Nebius — a position stemming from a $2 billion investment made in March.

The competitive landscape is not static. AMD introduced its Helios rack-scale system on Monday, positioning it against Nvidia’s Grace Blackwell and Vera Rubin platforms, and announced an expanded alliance with Microsoft to supply Helios with Instinct MI455X GPUs and Epyc Venice processors for Azure AI infrastructure starting in the second half of 2026. According to Futurum Research, Nvidia still commands more than 95% of the data-center GPU market, with AMD at roughly 4.5%, though AMD could reach 20–25% over the medium term.

Nvidia reports its next quarterly results on August 26. Analysts expect earnings per share of $2.07, more than double the $1.04 reported a year earlier, and revenue of $91.7 billion compared with $46.74 billion in the year-ago period. In the most recently reported quarter, revenue came in at $81.6 billion, up 20% sequentially. Technically, the stock is 8.69% above its 200-day moving average of 165.63 euros and less than 2% below its 50-day average, suggesting the long-term uptrend remains intact despite the recent pullback. Investors will be watching closely for updates on Vera-Rubin production progress and any further easing of export restrictions on high-end AI chips to regions such as the United Arab Emirates.